Introduction
============

Gastric cancer is the fifth most common cancer worldwide, with an estimated occurrence of almost one million new cases every year, with half of the world total occurring in East Asia \[[@b1-crt-2015-155]\]. In terms of mortality, it remains one of the most common causes of cancer related mortality, only second to lung cancer \[[@b2-crt-2015-155]\], as less than 50% of patients are eligible for complete resection, and, in spite of recent progress, expected survival duration with palliative treatment barely exceeds 1 year \[[@b3-crt-2015-155],[@b4-crt-2015-155]\].

*HER2* amplification or overexpression is known to occur in approximately 15%-20% of patients with gastric cancer. The pivotal Trastuzumab for Gastric Cancer (ToGA) trial \[[@b5-crt-2015-155]\] demonstrated that patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer may benefit from trastuzumab, an anti-HER2 monoclonal antibody. In the ToGA trial, patients assigned to receive trastuzumab in combination with chemotherapy showed significant improvement in overall survival (OS, 13.8 vs. 11.1 months), progression-free survival (PFS, 6.7 months vs. 5.5 months), and overall response rate (ORR, 47% vs. 35%). In addition, an exploratory analysis demonstrated that patients with strong protein expression (immunohistochemistry \[IHC\] 3\[+\] or IHC 2\[+\]/fluorescence *in situ* hybridization \[FISH\] \[+\]) were more likely to have favorable OS with the addition of trastuzumab (16.0 months vs. 11.8 months). With these results, trastuzumab was approved as a standard treatment option for HER2-positive gastric cancer patients.

Meanwhile, the subset analysis of the ToGA trial generated several questions. It is well-known that ethnicity matters in gastric cancer \[[@b6-crt-2015-155]\]. Not only in terms of epidemiology, histology, or pharmacodynamics, certain treatments which were effective for a Western population did not show similar efficacy in an Asian population, as in the AVAGAST trial \[[@b7-crt-2015-155]\]. In fact, in the subset analysis of the ToGA trial, OS benefit was not observed in the Asian population, while patients from America and Europe did benefit from the treatment. In addition, according to the subset analysis of the ToGA trial, patients with diffuse-type cancer who seldom harbor HER2 overexpression did not show OS benefit from trastuzumab-based treatment.

In the current study, we conducted a multicenter, retrospective analysis on HER2-positive gastric cancer patients from 12 tertiary institutes in Korea, who were treated with trastuzumab-based treatment in order to confirm whether the clinical outcomes are affected by Asian ethnicity or histology, and to provide further understanding of the disease nature of HER2-positive gastric cancer.

Materials and Methods
=====================

1. Patients
-----------

Patients diagnosed with HER2-positive unresectable or metastatic gastric cancer from 2009 to 2014 were included in the analysis. The inclusion criteria were as follows: (1) a pathologically confirmed diagnosis of gastric cancer; (2) HER2 positivity confirmed according to the criteria used in the ToGA trial, that is, either IHC 3(+) or IHC 2(+)/FISH (+); (3) treated with trasutuzumab-based chemotherapy as the first-line treatment. Combined therapy could be continued after six cycles according to physicians' decision. (4) Complete medical records, including demographics, site of primary tumor, and pathologic reports. The study was approved by the Institutional Review Board of the primary investigator's institute, Samsung Medical Center.

2. Clinicopathologic parameters
-------------------------------

Clinicopathologic parameters including age, sex, performance status, primary tumor site, Lauren's classification, World Health Organization (WHO) histologic classification, measurability of lesions, methods for HER2 confirmation, backbone chemotherapeutic regimen, and baseline laboratory findings were collected retrospectively from patients' medical records.

3. Statistical analysis
-----------------------

OS was measured from the date of diagnosis of an unresectable or metastatic disease to the date of death or last follow-up, and PFS was measured from the date of diagnosis of a metastatic or unresectable disease to the date of progressive disease, death, or last follow-up. All survival parameters were calculated using the Kaplan-Meier method and were compared using a log-rank test. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors ver. 1.0. p-values less than 0.05 were considered statistically significant, and all p-values corresponded to two-sided significance tests.

To assess whether higher HER2/CEP17 ratio affected PFS, patients were dichotomized according to good survival group (median PFS ≥ 6 months) versus poor survival group (median PFS \< 6 months). The optimal cutoff for HER2/CEP17 ratio for predicting a favorable PFS was determined using receiver operating characteristic (ROC) curve analyses, and further evaluation was performed using the area under the curve (AUC). All statistical analyses were performed using SPSS ver. 17 (SPSS Inc., Chicago, IL).

Results
=======

1. Demographics and baseline disease characteristics
----------------------------------------------------

A total of 168 patients from 12 institutes were eligible for the analysis. The median age of patients was 60 years (range, 27 to 85 years) and 118 patients (70.2%) were male. All patients were Asian. Regarding the location of the primary tumor, 161 cases (95.8%) were stomach cancer and seven cases (4.2%) were GEJ cancer. As many pathologists in Korea do not interpret Lauren's classification with biopsied specimens, only 78 cases had been confirmed using Lauren's classification, and among them, 44 (56.4%), 22 (28.2%), and 12 cases (15.4%) were found to be intestinal-type, diffuse-type, and mixed-type cancer, respectively. However, WHO histologic classification was confirmed in all cases, with 14 (8.3%), 63 (37.5%), 75 (44.6%), and 11 cases (6.5%) found to be well-differentiated, moderately-differentiated, poorly-differentiated tubular adenocarcinoma, and signet ring cell carcinoma, respectively. In terms of methods for HER2 confirmation, in 129 patients disease was confirmed by IHC 3(+), and by IHC 2-3(+)/FISH (+) in 59 patients whose median value of HER2/CEP17 ratio was 3.34 (range, 2.09 to 20.00). Other details are described in [Table 1](#t1-crt-2015-155){ref-type="table"}.

2. Clinical outcomes of trastuzumab-based therapy
-------------------------------------------------

Regarding the backbone regimen of the trastuzumab-based therapy, 145 patients (86.3%) had received capecitabine plus cisplatin, 14 patients (8.3%) had received 5- fluorouracil (5-FU) plus cispaltin, and nine patients had received other agents. Median number of cycles was six (range, 1 to 62) for both trastuzumab and chemotherapy. Tumor responses were as follows: 12 (7.1%) complete response, 73 (43.5%) partial response, 48 (28.6%) stable disease, 17 (10.1%) progressive disease, and 18 (10.7%) cases were not evaluable, resulting in 50.6% of ORR ([Table 2](#t2-crt-2015-155){ref-type="table"}).

With a median follow-up duration of 32.9 months (95% confidential interval \[CI\], 30.0 to 35.8), median PFS was 10.2 months (95% CI, 8.7 to 11.7), and median OS was 18.5 months (95% CI, 16.4 to 50.6). Considering that Asian patients usually achieve approximately 12 months of OS and 6 months of PFS, the numerical data of the current study may suggest that even in an Asian population, trastuzumab-based therapy could be beneficial for patients with HER2-positive gastric cancer.

Next, subset analysis was performed for survival according to the histologic differentiation. Patients with well-differentiated and moderately-differentiated tubular adenocarcinoma were categorized as the well-differentiated histologic (WDH) group, and poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma as poorly-differentiated histologic (PDH) group. Consequently, 77 (45.8%) and 86 (51.2%) patients were classified as the WDH and PDH group, respectively. The median PFS of the WDH group was slightly longer than that of the PDH group, which did not reach statistical significance (11.5 months \[95% CI, 8.1 to 14.9\] vs. 8.9 months \[95% CI, 7.2 to 10.6\], p=0.16) ([Fig. 1](#f1-crt-2015-155){ref-type="fig"}). However, the median OS of two groups was significantly different; 19.0 months (95% CI, 14.2 to 23.8) for the WDH group; 14.6 months (95% CI, 11.9 to 17.3) (p=0.025) for the PDH group ([Fig. 2](#f2-crt-2015-155){ref-type="fig"}). Again, in numerical perspectives, these data of PDH patients, that is, PFS of 8.9 months and OS of 14.6 months, are better than the data from the typical Asian trial, which might suggest that even patients of PDH could benefit from trastuzumab-based therapy. Other than histologic differentiation, Eastern Cooperative Oncology Group (ECOG) status and serum albumin level were associated with survival ([Table 3](#t3-crt-2015-155){ref-type="table"}).

ROC analysis was performed for 59 patients who were confirmed as FISH (+) if a certain HER2/CEP17 ratio could predict favorable PFS for trastuzumab-based treatment. However, we could not determine optimal cutoff values for favorable PFS ([Fig. 3](#f3-crt-2015-155){ref-type="fig"}) and the AUC was calculated as lower than 0.5. Higher ratios (3 or higher and 4 or higher) were not associated with prolonged PFS ([Table 4](#t4-crt-2015-155){ref-type="table"}).

Discussion
==========

Although several combinations have been introduced in treatment of unresectable or metastatic gastric cancer patients, their prognosis remains poor. As a significant interest in targeted therapies has emerged, a number of targeted agents have been evaluated in gastric cancer. However, most of them fell short of success \[[@b7-crt-2015-155]-[@b9-crt-2015-155]\], and trastuzumab is the only agent with a known predictive biomarker and proven efficacies. Clinical efficacy of ramucirumab and apatinib was recently demonstrated in refractory gastric cancer patients; however, their predictive biomarkers have not been found.

HER2 is a member of the epidermal growth factor receptor family which promotes cell proliferation and inhibits apopapoptosis, and its overexpression has been described in various human malignancies. Trastuzumab, a recombinant humanized anti-HER2 monoclonal antibody, was first developed as a targeted agent for HER2-positive breast cancer, and its unprecedented successes heralded the era of target therapy and relevant biomarkers in the field of oncology. As the carcinogenic roles of HER2 in gastric cancer had been suggested, a randomized phase III trial commenced to assess the clinical efficacy and safety of trastuzumab, which was followed by a great success.

Ethnicity and regional variations should always be considered in management of gastric cancer. Not only the nationwide screening policies, epidemiology, pathogenesis, anatomic location or dominant histology, treatment modalities including surgical approaches and adjuvant treatment also differ between Asian and Western countries \[[@b6-crt-2015-155]\]. In addition, several pharmacokinetic studies demonstrated that efficacy and tolerability of fluoropyrimidine, a major antineoplastic agent in management of gastric cancer, differ between Asian and Western people \[[@b10-crt-2015-155]\]. Owing to these factors, the clinical outcomes of Asian gastric cancer patients are superior to those of Western patients. Therefore, mindfulness of ethnicity is important in managing patients and in planning clinical trials as well. Given that HER2 overexpression is frequently found in GEJ and intestinal-type cancer, HER2 overexpression rate might be lower in Asians, who tend to have distal and diffuse-type cancers. However, several series of surveys demonstrated that HER overexpression rate was not low in Asians \[[@b11-crt-2015-155]\].

As prevalence of gastric cancer is high in Asia, many gastric cancer trials have been conducted with Asians. In the ToGA trial, among 584 patients, 319 (54.6%) were Asians, and, as described above, Asians per se, were not associated with OS benefit with trastuzumab-based treatment \[[@b5-crt-2015-155],[@b12-crt-2015-155]\]. However, this could result from the fact that Asian gastric cancer patients already have sufficient survival outcomes with chemotherapy alone, probably due to subsequent treatment which may attenuate the impact of effective combinations as shown in the AVAGAST trial \[[@b7-crt-2015-155]\]. The benefit of trastuzumab-based therapy in Asians might be suggested in two recent Asian trials. In a Japanese study, 53 patients were treated with trastuzumab combined with S-1 plus cisplatin, and their median PFS and OS were estimated as 7.8 months and 16.0 months \[[@b13-crt-2015-155]\]. And, in a Korean study, 55 patients treated with trastuzumab combined with capecitabine and oxaliplatin (XELOX) showed a median PFS of 9.8 months and a median OS of 21.0 months \[[@b14-crt-2015-155]\]. Along with these data, our retrospective analysis showed a median PFS and OS of 10.2 months and 18.5 months, respectively ([Table 5](#t5-crt-2015-155){ref-type="table"}). Considering that Asians usually achieve PFS of 5 to 6 months and OS of 12 to 13 months with the first-line fluoropyrimidine and platinum combinations \[[@b7-crt-2015-155],[@b15-crt-2015-155]\], these numerical data imply that Asians may also benefit from trastuzumab-based therapy in the same manner with Western people. However, prospective head-to-head comparative analyses are warranted in order to confirm the efficacy of trastuzumab-based therapy in this unique population.

Histologic subtype is one of the interesting issues in HER2-positive gastric cancer. Gastric cancer can be categorized according to two distinct histologic subtypes, intestinal and diffuse, which are distinct in their microscopic and gross appearance, epidemiology, pathogenesis, and prognosis \[[@b16-crt-2015-155]\]. Among them, diffuse-type gastric cancer is associated with poor response to treatment and early relapse, thereby a worse survival \[[@b17-crt-2015-155]\]. In the current study, we used WHO classification as a substitute for Lauren's classification, as many pathologists in Korea do not interpret Lauren's classification with endoscopic specimens due to fear of misreading, yet a high concordance between two systems has been observed \[[@b18-crt-2015-155]\]. Compared to the patients with WDH, the patients with PDH showed worse clinical outcomes in both PFS (8.9 months vs. 11.5 months, p=0.16) and OS (14.6 months vs. 19.0 months, p=0.025). As these data are not head-to-head comparisons, it is difficult to make a firm conclusion whether patients with PDH can benefit from trastuzumab-based therapy or not. Nonetheless, considering the numerical clinical data usually reported in Asians, our data may imply that even patients harboring PDH cancer could benefit from trastuzumab-based therapy, although the degree is somewhat limited compared to patients with WDH.

In the perspective of frequency of HER2 overexpression or amplification, it is more commonly found in intestinal-type cancer than diffuse-type cancer. In the ToGA trial, 51 out of 584 patients (8.7%) had diffuse-type cancer, and in the LOGiC trial, the differential became even more remarkable; 3.9% of patients (19/487) had diffuse-type cancer \[[@b19-crt-2015-155]\]. This dominance of intestinal-type cancer in the two trials looks suitable considering its disease nature. However, in our cohort, the number of patients with PDH (n=86, 51.2%) was slightly higher than that of patients with WDH (n=77, 45.8%). This could have resulted from the histologic distribution of gastric cancer patients in Asia. Several large studies from Asia demonstrated that diffuse-type or poorly-differentiated cancer was more predominant \[[@b15-crt-2015-155],[@b20-crt-2015-155]\]. Although these types of gastric cancer do not harbor HER2 overexpression very often, out-numbering of patients could draw the results. Similar to our finding, in the TyTAN trial, which recruited HER2-positive gastric cancer patients confined to Asia \[[@b21-crt-2015-155]\], only 43% of patients had intestinal-type gastric cancer.

A HER2/CEP17 ratio was recently suggested as a novel predictive marker for trastuzumab-based treatment. In a Spanish trial, 66 FISH positive patients were evaluated and HER2/CEP17 higher than 4.7 was identified as the cutoff value for prolonged OS \[[@b22-crt-2015-155]\]. In another report by Ock et al. \[[@b23-crt-2015-155]\], a HER2/CEP17 ratio of 4.48 clearly discriminated clinical outcomes. In our study, however, we failed to find optimal discriminating values for favorable PFS. This could have resulted from the small number of samples, and our FISH data did not come from a single laboratory. Tumor heterogeneity regarding the *HER2* amplification could also be another factor \[[@b24-crt-2015-155]\]. Further analysis is requested on this issue.

The current study has several limitations. Data were collected in a retrospective manner and from multiple institutes. This could draw somewhat inconsistent interpretation regarding the favorable tumor response, such as complete or partial responses. However, as we assessed PFS and OS, we believe the validity of the conclusive data and rather, it may reflect real world clinical outcomes. Although the backbone regimens are varied, most of them (98.2%) are the combination of fluoropyrimidine (5-FU and capecitabine) and platinum (cisplatin, oxaliplatin) which have similar efficacies and can be used interchangeably. And, as we focused on the efficacy of the treatment, the current analysis does not provide ethnic or histologic difference of safety issue.

Conclusion
==========

In conclusion, despite the result of subset analysis of the ToGA trial, we might conclude that irrespective of ethnicity or histologic subtypes, patients with HER2-positive gastric cancer can benefit from trastuzumab-based chemotherapy. Further analysis to find predictive biomarkers for these patients should be continued and ethnic difference and histologic subtypes should be considered for future clinical trials on gastric cancer patients.
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###### 

Demographics and baseline disease characteristics

  Characteristic                                                                       No. (%) (n=168)
  ------------------------------------------------------------------------------------ -----------------
  **Age, median (range, yr)**                                                          60 (27-85)
  **Sex**                                                                              
   Male                                                                                118 (70.2)
   Female                                                                              50 (29.8)
  **ECOG performance status**                                                          
   0                                                                                   45 (26.8)
   1                                                                                   115 (68.5)
   2                                                                                   7 (4.2)
   3                                                                                   1 (0.6)
  **Primary tumor site**                                                               
   Gastroesophageal junction                                                           7 (4.2)
   Stomach                                                                             161 (95.8)
  **Previous gastrectomy**                                                             
   Not done                                                                            99 (58.9)
   Subtotal gastrectomy                                                                45 (26.8)
   Total gastrectomy                                                                   24 (14.3)
  **Extent of disease**                                                                
   Locally advanced                                                                    54 (32.1)
   Metastatic                                                                          114 (67.9)
  **Disease measurability**                                                            
   Measurable                                                                          97 (57.7)
   Non-measurable                                                                      71 (42.3)
  **HER2 status**                                                                      
   IHC 3(+)/FISH not done                                                              109
   IHC 2(+)/FISH (+)                                                                   39
   IHC 3(+)/FISH (+)^[a)](#tfn2-crt-2015-155){ref-type="table-fn"}^                    20
  **WHO histologic classification**                                                    
   Well-differentiated tubular adenocarcinoma                                          14 (8.3)
   Moderately-differentiated tubular adenocarcinoma                                    63 (37.5)
   Poorly-differentiated tubular adenocarcinoma                                        75 (44.6)
   Signet ring cell carcinoma                                                          11 (6.5)
   Others                                                                              5 (3.0)
  **Lauren\'s classification (n=78)**                                                  
   Intestinal                                                                          44 (56.4)
   Diffuse                                                                             22 (28.2)
   Mixed                                                                               12 (15.4)
  **Specimens confirmed as HER2 (+)^[b)](#tfn3-crt-2015-155){ref-type="table-fn"}^**   
   Surgical specimen                                                                   61
   Endoscopic biopsied specimen                                                        108
   Specimens from metastatic site                                                      12

ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; FISH, fluorescence *in situ* hybridization; WHO, World Health Organization.

Both IHC and FISH were performed in these patients,

Multiple specimens could be sampled in a single patient.

###### 

Clinical outcomes of trastuzumab-based treatment

  Variable                                             No. (%)
  ---------------------------------------------------- ------------------
  **Backbone regimen**                                 
   XP                                                  145 (86.3)
   FP                                                  14 (8.3)
   XELOX                                               6 (3.6)
   Capecitabine                                        2 (1.2)
   None (trastuzumab monotherapy)                      1 (0.6)
  **Tumor response**                                   
   Complete response                                   12 (7.1)
   Partial response                                    73 (43.5)
   Stable disease                                      48 (28.6)
   Progressive disease                                 17 (10.1)
   Missing                                             18 (10.7)
  **Overall survival, median (95% CI, mo)**            18.5 (16.4-50.6)
  **Progression-free survival, median (95% CI, mo)**   10.2 (8.8-11.6)

XP, capecitabine plus cisplatin; FP, 5-fluorouracil (5-FU) plus cisplatin; XELOX, capecitabine and oxaliplatin; CI, confidence interval.

###### 

Survival durations according to other clinicolaboratory factors

  Variable             No.   PFS, median (95% CI)   p-value   OS, median (95% CI)   p-value
  -------------------- ----- ---------------------- --------- --------------------- ----------
  **Albumin (g/dL)**                                                                
   ≤ 3.0               19    7.3 (3.9-10.7)         0.012     14.3 (7.2-21.4)       0.064
   ≥ 3.1               148   9.4 (5.1-13.7)                   18.7 (17.0-20.4)      
  **ECOG PS**                                                                       
   0                   45    14.4 (7.8-21.0)        0.005     43.4 (7.7-79.1)       \< 0.001
   1 or 2              122   9.2 (8.7-11.7)                   15.7 (13.0-18.4)      

PFS, progression-free survival; CI, confidence interval; OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group performance status.

###### 

HER2/CEP17 ratio and progression-free survival (n=59)

  Ratio    No.   PFS, median (95% CI)   p-value
  -------- ----- ---------------------- ---------
  0-2.99   22    10.2 (6.4-14.0)        0.64
  ≥ 3      37    9.8 (5.1-13.7)         \-
  0-3.99   34    9.9 (6.8-13.0)         0.984
  ≥ 4      25    9.8 (5.7-13.9)         \-

PFS, progression-free survival; CI, confidence interval.

###### 

Comparison of clinical outcomes of anti-HER2 trials for Asians

  Trial                                                                                Regimen                                             ORR (%)   PFS, median (95% CI, mo)   OS, median (95% CI, mo)   No.
  ------------------------------------------------------------------------------------ --------------------------------------------------- --------- -------------------------- ------------------------- -----
  HERBIS-1 \[[@b13-crt-2015-155]\]                                                     Trastuzumab (8→6 mg/kg) SP                          68        7.8 (6.0-8.8)              16.0 (13.3-N/A)           53
  Ryu et al. \[[@b14-crt-2015-155]\]                                                   Trastuzumab (8→6 mg/kg) XELOX                       68        9.8 (7.0-12.6)             21.0 (6.4-35.7)           55
  Present study                                                                        Trastuzumab (8→6 mg/kg) Various backbone regimens   50.6      10.2 (8.7-11.7)            18.5 (16.4-50.6)          168
  ToGA trial \[[@b12-crt-2015-155]\]^[a)](#tfn8-crt-2015-155){ref-type="table-fn"}^    Trastuzumab (8→6 mg/kg) XP or FP                    64.4      6.2 (5-7)                  15.9 (12-25)              51
  LOGiC trial \[[@b19-crt-2015-155]\]^[b)](#tfn9-crt-2015-155){ref-type="table-fn"}^   Lapatinib 1,250 mg every day XELOX                  N/A       N/A                        16.5 (13.3-20.2)          100

ORR, objective response rate; PFS, progression-free survival; CI, confidence interval; OS, overall survival; SP, S-1 plus cisplatin; XELOX, capecitabine and oxaliplatin; XP, capecitabine plus cisplatin; FP, 5-fluorouracil plus cisplatin; N/A, not available.

Japanese subset analysis,

Asian subset analysis.
